These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1820900)

  • 1. The effect of food and antacids on lansoprazole absorption and disposition.
    Delhotal-Landes B; Cournot A; Vermerie N; Dellatolas F; Benoit M; Flouvat B
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():315-20. PubMed ID: 1820900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods.
    Chun AH; Erdman K; Zhang Y; Achari R; Cavanaugh JH
    Clin Ther; 2000 Feb; 22(2):231-6. PubMed ID: 10743982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
    Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
    Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe.
    Gremse DA; Donnelly JR; Kukulka MJ; Lloyd E; Lee C
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1211-5. PubMed ID: 15153174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of a crushed pantoprazole tablet after buffering with sodium hydrogencarbonate or magaldrate relative to the intact enteric coated pantoprazole tablet.
    Ley LM; Stahlheber-Dilg B; Sander P; Huber R; Mascher H; Lücker PW
    Methods Find Exp Clin Pharmacol; 2001; 23(1):41-5. PubMed ID: 11413863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Decreased plasma levels of omeprazole after coadministration with magnesium-aluminium hydroxide dry suspension granules].
    Iwao K; Saitoh H; Takeda K; Azuumi Y; Takada M
    Yakugaku Zasshi; 1999 Mar; 119(3):221-8. PubMed ID: 10198597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
    Portolés A; Calvo A; Terleira A; Laredo L; Resplandy G; Gorostiaga C; Moreno A
    J Clin Pharmacol; 2006 Oct; 46(10):1195-203. PubMed ID: 16988209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers.
    Yasuda S; Higashi S; Murakami M; Tomono Y; Kawaguchi M
    Int J Clin Pharmacol Ther; 1999 May; 37(5):249-53. PubMed ID: 10363624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation.
    Chun AH; Erdman K; Chiu YL; Pilmer BL; Achari R; Cavanaugh JH
    Clin Ther; 2002 Aug; 24(8):1322-31. PubMed ID: 12240782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel bioavailability: absence of influence of food or antacids.
    McEwen J; Strauch G; Perles P; Pritchard G; Moreland TE; Necciari J; Dickinson JP
    Semin Thromb Hemost; 1999; 25 Suppl 2():47-50. PubMed ID: 10440423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of concomitantly administered antacids on the bioavailability of lornoxicam, a novel highly potent NSAID.
    Dittrich P; Radhofer-Welte S; Magometschnigg D; Kukovetz WR; Mayerhofer S; Ferber HP
    Drugs Exp Clin Res; 1990; 16(2):57-62. PubMed ID: 2401187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and absolute bioavailability of lansoprazole.
    Gerloff J; Mignot A; Barth H; Heintze K
    Eur J Clin Pharmacol; 1996; 50(4):293-7. PubMed ID: 8803522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole.
    Freston JW; Pilmer BL; Chiu YL; Wang Q; Stolle JC; Griffin JS; Lee CQ
    Aliment Pharmacol Ther; 2004 May; 19(10):1111-22. PubMed ID: 15142201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube.
    Freston JW; Kukulka MJ; Lloyd E; Lee C
    Aliment Pharmacol Ther; 2004 Aug; 20(4):407-11. PubMed ID: 15298634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of an aluminium-hydroxide containing antacid on the oral bioavailability of pirenzepine.
    Vergin H; Herrlinger C; Gugler R
    Arzneimittelforschung; 1989 Apr; 39(4):520-3. PubMed ID: 2751741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers.
    Krishna G; Kisicki JC; Olsen S; Grasela DM; Wang Z
    Pharmacotherapy; 2007 Jul; 27(7):963-9. PubMed ID: 17594201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules.
    Amer F; Karol MD; Pan WJ; Griffin JS; Lukasik NL; Locke CS; Chiu YL
    Clin Ther; 2004 Dec; 26(12):2076-83. PubMed ID: 15823771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.
    Tran A; Rey E; Pons G; Pariente-Khayat A; D'Athis P; Sallerin V; Dupont C
    Clin Pharmacol Ther; 2002 May; 71(5):359-67. PubMed ID: 12011821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the possible influence of the absorption of vinpocetine with concomitant application of magnesium-aluminium-hydroxide gel.
    Lohmann A; Grobara P; Dingler E
    Arzneimittelforschung; 1991 Nov; 41(11):1164-7. PubMed ID: 1810262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
    Ushiama H; Echizen H; Nachi S; Ohnishi A
    Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.